WELCOME!

Today’s Topic:

Medication Assisted Treatment Update

What medications should I consider for the treatment of alcohol use disorders?

Daniel Maglioizzi, MD

PANELISTS:
MARK DUNCAN, MD, RICK RIES, MD, KARI STEPHENS, PHD, AND BARB MCCANN, PHD
ALCOHOL USE DISORDER: MEDICATION-ASSISTED TREATMENT

DANIEL MAGLIOZZI: ADDICTION PSYCHIATRY FELLOW - UNIVERSITY OF WASHINGTON
GENERAL DISCLOSURES

The University of Washington School of Medicine also gratefully acknowledges receipt of educational grant support for this activity from the Washington State Legislature through the Safety-Net Hospital Assessment, working to expand access to psychiatric services throughout Washington State.
GENERAL DISCLOSURES

UW PACC is also supported by Coordinated Care of Washington
SPEAKER DISCLOSURES

✓ None
SPEAKER DISCLOSURES

✓ No conflicts of interest

PLANNER DISCLOSURES

The following series planners have no relevant conflicts of interest to disclose:

Mark Duncan MD
Barb McCann PhD
Anna Ratzliff MD PhD
Rick Ries MD
Kari Stephens PhD

Niambi Kanye
Betsy Payn
Diana Roll
Cara Towle MSN RN
OBJECTIVES

• Discuss FDA approved medications for alcohol use disorder
• Discuss other evidence-based medications for alcohol use disorder
• Practice clinical decision-making as it relates to alcohol use disorder through case presentations
GABA Glutamate

Homeostasis

Intoxication/Occasional Alcohol Use

Sedation, psychomotor retardation

Neuroadaptation-chronic alcohol use:
Up regulation of Glutamate
and down regulation of GABA

Withdrawal State:
Unopposed Glutamate up regulation
without alcohol mediated GABA stimulation

Anxiety, Insomnia, psychomotor agitation
Alcohol Use Disorder

- FDA Approved Medications:
  - Naltrexone
  - Disulfiram
  - Acamprosate

- Others:
  - Gabapentin
  - Anticonvulsants
  - More...
Naltrexone

= Endogenous Opioid

Rush of Endogenous Opioids

INCREASED STIMULATION OF THE DOPAMINE REWARD SYSTEM
Naltrexone (PO)

Meta-analysis: Oral naltrexone vs. placebo – participants returning to heavy drinking

Srisurapanont & Jarusuraisin, 2006
Naltrexone in Co-occurring Depression

Pettinati et al., 2009. Combining Sertaline (200 mg/d) and Naltrexone (100 mg/d) for Co-occurring Depression and Alcohol Dependence
Extended Release IM Naltrexone

- 24-week multicenter, randomized, double-blind, placebo-controlled study
- 624 alcohol-dependent patients (DSM-IV)
- Treatment consisted of 12 sessions of low-intensity psychosocial intervention (BRENDA) plus 6 monthly IM injections of either:
  - Placebo
  - XR-NTX 190 mg
  - XR-NTX 380 mg

Garbutt et al, 2005. Efficacy and Tolerability of Long-Acting Injectable Naltrexone for Alcohol Dependence: A Randomized Controlled Trial
Extended Release IM Naltrexone

- Pretreatment: 19.3
- Placebo: 6.0
- Naltrexone (190mg): 4.5
- Naltrexone (380mg): 3.1

*P<0.05 vs placebo

↓48%
Naltrexone

- Decreases cravings and amount of alcohol consumed during binges
- PO 50-150mg daily; IM 380mg q28days

Pros:
- IM version available in US
- Good for harm reduction
- Generally well-tolerated

Cons:
- Common SEs: nausea, diarrhea, HA, insomnia, dizziness
- Can’t use with opiates
- Caution if hepatic impairment
Disulfiram
**Disulfiram**

*Fuller et al., 1986*: Partially blinded, RCT in 9 VA's

### Alcohol Consumption During the Study

<table>
<thead>
<tr>
<th></th>
<th>250 mg</th>
<th>1 mg</th>
<th>None</th>
</tr>
</thead>
<tbody>
<tr>
<td>Drinking Days</td>
<td>49.0±8.4</td>
<td>75.4±11.9</td>
<td>86.5±13.6</td>
</tr>
<tr>
<td>Reported by Subjects</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Drinking Days</td>
<td>68.0±11.2</td>
<td>108.7±14.7</td>
<td>116.4±16.3</td>
</tr>
<tr>
<td>Reported by SO's</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
Disulfiram

- Causes disulfiram-alcohol reaction to deter alcohol use
  - Flushing, sweating, N/V, HA, tachycardia
- 250mg daily
- Pros:
  - Generally well-tolerated
  - Demonstrated efficacy (when actually taking)
  - Some evidence to also reduce cocaine cravings
- Cons:
  - Risk of hepatotoxicity (1/25,000 patient-years of tx)
  - Poor compliance (works better if someone monitors)
  - Can’t use any products containing alcohol
  - Cannot use for harm-reduction
Acamprosate

**Homeostasis**

- GABA
- Glutamate

**Intoxication/Occasional Alcohol Use**

- GABA
- Glutamate
  
  *Sedation, psychomotor retardation*

**Neuroadaptation-chronic alcohol use:**

- GABA
- Glutamate
  
  *Up regulation of Glutamate and down regulation of GABA*

**Withdrawal State:**

- GABA
- Glutamate
  
  *Unopposed Glutamate up regulation without alcohol mediated GABA stimulation*
  
  *Anxiety, Insomnia, psychomotor agitation*
Acamprosate

- Restores balance of GABA/glutamate activity
- 666mg (two 333mg Tabs) TID
- Pros:
  - Generally well-tolerated (diarrhea 10-20%, rash <5%)
  - Good option in people with hepatic disease
  - Can be used for harm-reduction
- Cons:
  - Caution in renal impairment (renally excreted)
  - Difficult dosing schedule
  - Studies showing efficacy mostly done in Europe
Gabapentin

- Some studies demonstrate improvements in abstinence rate, time to first drink, number of heavy drinking days, and drinks per heavy drinking day
- 1 recent RCT shows gabapentin XR not as effective as IR
- Dose 600mg TID (this may vary)

Pros:
- Makes for a smooth transition from detox
- Helps with insomnia and negative affect from prolonged withdrawal

Cons:
- Uncertain efficacy
- Difficult dosing schedule
Gabapentin with Naltrexone

Anton, Myrick, et al., 2011: Gabapentin (up to 1200 mg/d) Combined with Naltrexone (50 mg/d) for Treatment of Alcohol Dependence
Anticonvulsants

- **Topiramate**
  - Some evidence for efficacy in abstinence, time to first drink, heavy drinking days, and drinks per heavy drinking day
  - Mixed evidence in ability to treat cocaine use disorder
  - Main limitation is cognitive slowing
  - Dose: 100-150mg BID

- **Valproic Acid**
  - Some evidence for decrease in heavy drinking days and drinks per heavy drinking day
  - Dose: 500mg TID

- **Carbamazepine**
  - Some evidence for benefits similar to topiramate
  - Dose: 800mg-1200mg per day
# Baclofen

<table>
<thead>
<tr>
<th>Drug</th>
<th>Dosage</th>
<th>Mechanism</th>
<th>Metabolism</th>
<th>Excretion</th>
<th>ALD patients</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>FDA approved for AUD</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Disulfiram</td>
<td>250-500 mg q.d.</td>
<td>Acetaldehyde dehydrogenase inhibitor</td>
<td>Hepatic</td>
<td>Hepatic</td>
<td>No</td>
</tr>
<tr>
<td>Naltrexone</td>
<td>50 mg q.d. (oral) 380 mg monthly i.m.</td>
<td>μ and k-opioid receptor antagonists</td>
<td>Hepatic</td>
<td>Renal</td>
<td>No</td>
</tr>
<tr>
<td>Nalmefene</td>
<td>18 mg as needed</td>
<td>μ and δ-opioid receptor antagonist k-opioid receptor partial-agonist</td>
<td>Hepatic</td>
<td>Renal</td>
<td>No data</td>
</tr>
<tr>
<td>Acamprosate</td>
<td>666 mg t.i.d.</td>
<td>N-metil-D-aspartate receptor antagonist</td>
<td>Minimal</td>
<td>Renal</td>
<td>Limited data, probably yes</td>
</tr>
<tr>
<td><strong>Not FDA approved for AUD</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Sodium oxybate</td>
<td>50 mg/kg/day</td>
<td>GABAB receptor agonist</td>
<td>Hepatic</td>
<td>Hepatic</td>
<td>Limited data, probably yes</td>
</tr>
<tr>
<td>Topiramate</td>
<td>300 mg q.d.</td>
<td>Facilitates GABAA transmission reduces glutamatergic activity</td>
<td>Hepatic</td>
<td>Renal</td>
<td>No data, probably yes</td>
</tr>
<tr>
<td>Ondansetron</td>
<td>1-16 μg/kg b.i.d.</td>
<td>5-HT3 receptor antagonist</td>
<td>Hepatic</td>
<td>Renal</td>
<td>No data, probably yes</td>
</tr>
<tr>
<td><strong>Baclofen</strong></td>
<td>10-20 mg t.i.d.</td>
<td>GABAB receptor agonist</td>
<td>Minimal</td>
<td>Renal</td>
<td>Yes</td>
</tr>
<tr>
<td>Gabapentin</td>
<td>900-1800 mg t.i.d.</td>
<td>GABA transmission modulator</td>
<td>Minimal</td>
<td>Renal</td>
<td>No data, probably yes</td>
</tr>
<tr>
<td>Varenicline</td>
<td>2 mg q.d.</td>
<td>Nicotinic acetylcholine receptor partial agonist</td>
<td>Minimal</td>
<td>Renal</td>
<td>No data, probably yes</td>
</tr>
<tr>
<td>Metadoxine</td>
<td>500 mg t.i.d.</td>
<td>Acetaldehyde dehydrogenase activity enhancer</td>
<td>Oxidative</td>
<td>Metabolic</td>
<td>Yes</td>
</tr>
</tbody>
</table>

Other Meds Used

- Grade C Evidence for:
  - Varenicline
  - Prazosin
  - Oxcarbazapine
  - Lamotrigene
  - Pregabalin
  - Tiagabine
  - Levetiracetam
  - Ondansetron
Case #1

- 39yo M w/ h/o severe alcohol/cocaine use disorder and depression; no medical problems or h/o complicated withdrawal

- Alcohol use disorder
  - Currently on naltrexone 100mg daily
  - Still drinks 2-3 beers most nights, with occasional nights where he binges up to “10 beers and a couple shots”
    - Previously was drinking nearly a case per day
  - Patient’s stated goal: complete abstinence
Case #1 Continued

- Cocaine use disorder
  - Currently using almost daily with significant cravings
  - Engaged in substance use group therapy/NA
  - Never tried MAT

- Depression
  - Taking 200mg sertraline daily
  - Has ongoing mild depressive symptoms

- Homeless with minimal social support
What medication changes would you make next?

A. Add disulfiram 250mg daily to further treat alcohol use disorder and reduce cocaine cravings

B. Start disulfiram 250mg daily and stop naltrexone as combination therapy is not effective

C. Switch to long-acting injectable naltrexone for improved compliance

D. Augment sertraline with bupropion, as this can help reduce cocaine cravings and better treat depression

E. Start topiramate, titrate to 100mg BID, and stop naltrexone, as this can treat both alcohol and cocaine use
What medication changes would you make next?

**A. Add disulfiram 250mg daily to further treat alcohol use disorder and reduce cocaine cravings**

B. Start disulfiram 250mg daily and stop naltrexone as combination therapy is not effective

C. Switch to long-acting injectable naltrexone for improved compliance

D. Augment sertraline with bupropion, as this can help reduce cocaine cravings and better treat depression

E. Start topiramate, titrate to 100mg BID, and stop naltrexone, as this can treat both alcohol and cocaine use
Percent of cocaine/alcohol use disorder patients with 3+ consecutive weeks of abstinence from both cocaine/alcohol in an 11-week clinical trial:

Pettinati HM et al. Addict Behav. (2008)
Case #2

- 63 y/o white female with metastatic hepatocellular carcinoma (HCC) with vascular involvement, cirrhosis, HCV, unspecified cognitive impairment, and severe EtOH use disorder

- Alcohol use:
  - Use disorder for several decades
  - Five months of sobriety prior to HCC diagnosis
  - Relapse after diagnosis
  - Uncertain amount
  - She and her partner downplay drinking
  - Opiate pain meds withdrawn given ongoing alcohol use, and patient’s goal is to get pain meds back
Case #2 Continued

- Hepatocellular carcinoma:
  - Diagnosed in January 2018
  - Received debulking surgery in March 2018
  - Now on palliative Nivolumab (has alcohol in the IV fluid)
- Unspecified cognitive impairment
  - Hepatic encephalopathy vs. alcohol-related vs. multifactorial
  - Grossly normal LFT's but INR was 1.4-1.7
What would you recommend?

A. Naltrexone (oral or long acting injectable)
B. Disulfiram
C. Alcoholics Anonymous
D. Gabapentin
E. Baclofen
F. Topiramate
What would you recommend?

A. Naltrexone (oral or long acting injectable)
B. Disulfiram
C. Alcoholics Anonymous
D. Gabapentin
E. Baclofen
F. Topiramate
## Baclofen

<table>
<thead>
<tr>
<th>Drug</th>
<th>Dosage</th>
<th>Mechanism</th>
<th>Metabolism</th>
<th>Excretion</th>
<th>ALD patients</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>FDA approved for AUD</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Disulfiram</td>
<td>250-500 mg q.d.</td>
<td>Acetaldehyde dehydrogenase inhibitor</td>
<td>Hepatic</td>
<td>Hepatic</td>
<td>No</td>
</tr>
<tr>
<td>Naltrexone</td>
<td>50 mg q.d. (oral) 380 mg monthly i.m.</td>
<td>μ and k-opioid receptor antagonis</td>
<td>Hepatic</td>
<td>Renal</td>
<td>No</td>
</tr>
<tr>
<td>Nalmefene</td>
<td>18 mg as needed</td>
<td>μ and δ-opioid receptor antagonist k-opioid receptor partial-agonist</td>
<td>Hepatic</td>
<td>Renal</td>
<td>No data</td>
</tr>
<tr>
<td>Acamprosate</td>
<td>666 mg t.i.d.</td>
<td>N-Metil-D-aspartate receptor antagonist</td>
<td>Minimal</td>
<td>Renal</td>
<td>Limited data, probably yes</td>
</tr>
<tr>
<td><strong>Not FDA approved for AUD</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Sodium oxybate</td>
<td>50 mg/kg/day</td>
<td>GABAB receptor agonist</td>
<td>Hepatic</td>
<td>Hepatic</td>
<td>Limited data, probably yes</td>
</tr>
<tr>
<td>Topiramate</td>
<td>300 mg q.d.</td>
<td>Facilitates GABAA transmission reduces glutamatergic activity</td>
<td>Hepatic</td>
<td>Renal</td>
<td>No data, probably yes</td>
</tr>
<tr>
<td>Ondansetron</td>
<td>1-16 μg/kg b.i.d.</td>
<td>5-HT3 receptor antagonist</td>
<td>Hepatic</td>
<td>Renal</td>
<td>No data, probably yes</td>
</tr>
<tr>
<td>Baclofen</td>
<td>10-20 mg t.i.d.</td>
<td>GABAB receptor agonist</td>
<td>Minimal</td>
<td>Renal</td>
<td>Yes</td>
</tr>
<tr>
<td>Gabapentin</td>
<td>900-1800 mg t.i.d.</td>
<td>GABA transmission modulator</td>
<td>Minimal</td>
<td>Renal</td>
<td>No data, probably yes</td>
</tr>
<tr>
<td>Varenicline</td>
<td>2 mg q.d.</td>
<td>Nicotinic acetylcholine receptor partial agonist</td>
<td>Minimal</td>
<td>Renal</td>
<td>No data, probably yes</td>
</tr>
<tr>
<td>Metadoxine</td>
<td>500 mg t.i.d.</td>
<td>Acetaldehyde dehydrogenase activity enhancer</td>
<td>Oxidative</td>
<td>Metabolic</td>
<td>Yes</td>
</tr>
</tbody>
</table>